Drug Discovery

A path to the medicines of tomorrow

SBP paves the way by blending innovative medical research with robust drug discovery to develop treatments that directly impact patient lives.


SBP has the scientific expertise and technology platforms necessary to develop new therapeutics that address unmet clinical needs of patients. Our journey starts at the beginning – establishing innovative disease targets – and continues until our drug therapies are ready for patient testing.
 
 

Our Drug Discovery Groups

Prebys Center for Drug Discovery

The Conrad Prebys Center for Chemical Genomics (Prebys Center) is SBP’s comprehensive center for drug discovery and chemical biology. With our extensive pharmaceutical/biotech drug discovery and development experience, we are well-positioned to drive projects toward an end goal that will ultimately benefit patients. We have projects in all stages of drug discovery, from target I. D. and validation through preclinical development. We have a strong track record of being the partner of choice for academic, foundation and pharmaceutical partners, as well as generating original research and leads within our group.
 

Learn More

cell images
cell image
Translational Medicine Accelerator

The TMA identifies and advances lab discoveries with the greatest potential to address unmet clinical needs.
 

Learn More

The Institute’s Cancer Center is one of only seven NCI-designated basic cancer research centers in the nation. We couple fundamental biological research with early translational studies to find new, innovative therapies that restore hope to cancer patients and their families.

Learn More

The Center for Metabolic Origins of Disease studies common diseases that have reached pandemic scale including obesity, type 2 diabetes and cardiovascular complications. We have established an exciting environment that promotes multi-disciplinary discovery research toward breakthrough preventive and therapeutic strategies.

Learn More

Infectious diseases such as HIV/AIDS and tuberculosis continue to rank high among global mortality factors, especially in developing countries, and systemic inflammation has been identified as a root case of many chronic disorders in the developed world.

Learn More

Diseases associated with aging and development are already a leading cause of death and disability, and their prevalence is rising fast. By 2050, the number of Alzheimer’s patients age 65 and older may nearly triple from 5 million to 13.8 million.

Learn More

Diseases that predominantly affect children are too often unaddressed by the biopharmaceutical industry and government funding agencies. Rare childhood diseases – those affecting fewer than 200,000 in the U.S – are especially overlooked.

Learn More

SBP DRUG DISCOVERY PIPELINE
A drug discovery pipeline is created in distinct stages. At SBP, we start at the beginning—establishing innovative disease targets—and continue until it’s time to test drugs in patients. At that point, we partner with organizations such as hospitals, clinical research organizations and pharmaceutical companies to conduct clinical trials in phases designed to answer specific research questions.

 

 
SBP drug discovery projects by disease area
Drug discovery projects